Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC10A1 | Q14973 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296661 | 0.89 | MAPK1 (0.43) | MAPK1KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL21296716 | 0.86 | MAPK1 (0.46) | MAPK1KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL21296646 | 0.84 | MAPK1 (0.47) | MAPK1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL25706774 | 0.83 | SLC10A1 (0.44) | MAPK1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL25706772 | 0.80 | SLC10A1 (0.44) | MAPK1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL21378230 | 0.79 | SLC10A1 (0.48) | MAPK1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL21378231 | 0.79 | SLC10A1 (0.48) | MAPK1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL19900871 | 0.78 | KDM4E (0.44) | MAPK1KDM4EMCL1KMT2AMEN1 | |
| SCHEMBL21296685 | 0.77 | MAPK1 (0.60) | MAPK1KDM4EMCL1KMT2AMEN1 | |
| SCHEMBL23223828 | 0.75 | MAPK1 (0.63) | MAPK1KDM4EKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-111788204-B | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3759109-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-111788204-A | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| WO-2019165374-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | MAPK1 3270/4885KDM4E 1616/4885MCL1 905/4885 |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | MAPK1 3270/4885KDM4E 1616/4885MCL1 905/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | MAPK1 3270/4885KDM4E 1616/4885MCL1 905/4885 |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | MAPK1 3270/4885KDM4E 1616/4885MCL1 905/4885 |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | MAPK1 3270/4885KDM4E 1616/4885MCL1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.